Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement-Reference-Cited by-同舟云学术

Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement

Published:2017-02-27 Issue:4 Volume:22 Page:480-483
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Wehrli Marc¹,Oppliger Leibundgut Elisabeth²,Gattiker Heinrich H.³,Manz Markus G.¹,Müller Antonia M.S.¹,Goede Jeroen S.¹

Affiliation:

1. Division of Hematology University Hospital Zurich, Zurich, Switzerland

2. Division of Hematology Inselspital University Hospital Bern, Bern, Switzerland

3. Seefeldstrasse 45, 8008, Zurich, Switzerland

Abstract

Abstract This brief communication reports on a patient with an exceedingly rare “8p11 (eight-p-eleven) myeloproliferative syndrome” (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2016-0354

Reference14 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

2. Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1;Yamamoto;PLoS One,2015

3. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33);Guasch;Blood,2000

4. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: Report of a new case and review of the literature;Mozziconacci;Leuk Res,2008

5. 8p11 myeloproliferative syndrome: A review;Jackson;Hum Pathol,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different phenotype relapse of myeloid/lymphoid neoplasms with FGFR1 rearrangement with long remission;Pediatric Blood & Cancer;2023-10-13

2. FGFR families: biological functions and therapeutic interventions in tumors;MedComm;2023-09-23

3. Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement Presenting with Polycythemia Vera and T-cell Acute Lymphoblastic Leukemia.;Cancer Genetics;2023-08

4. The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy;Frontiers in Oncology;2022-11-03

5. Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling;Cells;2021-06-09